Actuate Therapeutics
Lantern is accelerating the development of Actuate Therapeutic’s drug candidate, Elraglusib (9-ING-41), using AI insights produced by RADR®
RADR® has been demonstrating remarkable capabilities in collaboration with Actuate Therapeutics. By predicting patient response with an accuracy exceeding 88%, RADR has identified a subset of metastatic melanoma patients esistant to PD-1 therapies who may benefit from Elraglusib. The collaboration has yielded valuable insights, incorporating new data such as RNA, ctDNA, and protein biomarkers. These findings are instrumental in shaping the design of an upcoming Phase 2 clinical trial. Additionally, underlining the strategic partnership, Lantern Pharma has received equity in Actuate.
